M. Professeur CHRISTIAN ROUX

Bibliographie

• Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial

  2025

  ArticleThe Lancet Rheumatology

• Deletion of PPARα in mouse brown adipocytes increases their De Novo Lipogenesis

  2025

  ArticleMolecular metabolism

• Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial

  2025

  ArticleThe Lancet Rheumatology

• Association between osteoporosis and periodontitis

  2025

  ArticleJoint Bone Spine

• Regulation of UCP1 expression by PPARα and pemafibrate in human beige adipocytes

  2025

  ArticleLife Sciences

• Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

  2024

  ArticleRheumatology

• Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study

  2024

  ArticleRheumatology

• Development of Spinal Enthesopathies in Adults With X-linked Hypophosphatemia

  2023

  ArticleJournal of Clinical Endocrinology and Metabolism

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

• CABINET PRIVE DU DR CHRISTIAN ROUX

  CHR PASTEUR II — 30 AVENUE DE LA VOIE ROMAINE, 06000 Nice

  Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• CHU DE NICE HOPITAL PASTEUR

  30 Avenue DE LA VOIE ROMAINE, 06001 Nice

  ☎ 0492037777Hospitalier🏥 Centre CHU ↗🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (7)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• Embolisation des artères géniculées dans la gonarthrose : « Il faut mener d’autres études contrôlées » - lequotidiendumedecin.fr

  📰 lequotidiendumedecin.fr · 30/09/2025

  <a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNeUE0S0dzUkw0S2JieUE0cEJ5RUktUExzZmV1YTJyT0hPWVR6V21DNlZhWEZCX2pjR0UwVGNGT09Vb1VyMXZIcUVwSi1LZUtWZGt6R2luclNMSTF3M1ZLalpqczhfdXFQQmNSNG44ZGVKQWlxN1VKVGlic25SUTZRbXp3SFVMWmRJN2RqY1djN2FYdXVaOUhBaEZ2cWEzV3ZMTmd5UFJMRC1BbWVvcWFUV0x5X2xnMGQzOD

• Un motard allemand s'encastre sous une voiture et se tue sur la RN202 - Nice-Matin

  📰 Nice-Matin · 24/09/2025

  <a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQY3dhYmhHeVVXSjhBanJVMUowd2ZwYXg4VzJsdHdiQ24zYUJoOU9JbGFlbzZyZVoxWjU0b0EzSVE1MUNWRE5PdE1pdm5DcGpEcnNCN1Jvdm1kbTRLQnZTTXNCblUwMERVemt6YjFrQnczSThqcWZXNTdoMVdkOXZwdnMwLUZYa0RYY2hGNXB4TFRST0J4Rk1WR1l3cHYxOFRkYnNsNzVCRW10c0hhQkxveWNZX05pZw?oc=

• L’arthrose du genou donne du cartilage à retordre - Le Moniteur des pharmacies

  📰 Le Moniteur des pharmacies · 12/08/2025

  <a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPYzNPZVRFcmNxRnhLWWVQcDRfRjBjaFMxVUU4eGVDQjhvemg4V2pJa1lHQkFHTEJSYUt1LUNiUW9ybXJ4bGdoTndRMDFTUVhyRjQwaXJpazhSTE16VC10UnlNVXFRQjFNUWdSMHNYeVJBYkozNUhFQ09PQktTNWd5aFk2bElrZGYxcmpINE1BTnYyU2t0bDdWX0w4WTRMbmFGN3pDckMxWnBrMVBfLTNWdnRhZnNkZU1mVn

• Douleurs persistantes après une prothèse de genou? Une solution testée au CHU de Nice - Nice-Matin

  📰 Nice-Matin · 17/02/2025

  <a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcHJSYWtEc0N4TUUtYmN0dlo3Zk1sLTl3eDdBSkxkcnpILURMRVpRX0xyM2dreGRfaGlzOFk0bm9HNFRWNTdIX1BndE0wY3lTU0UwdFZ1SlY0MjF2U1g1d1Y3d0ljQVhDek5CS3Q2bVM0YjVoYy1CMTZlM0lVSU1ZdTRiMmd4cDFTR0FjckpwLWg0eTljNkxsbldvQ196Q19yQi1EOWh4a0pyajdQdGd2WU9NcGthZHRZWU

• Nice : un nouveau traitement pour soigner l'arthrose digitale - France 3 Régions

  📰 France 3 Régions · 06/01/2020

  <a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPNUFzblh0YXJ1WVQ4MUVXOUJIR0Z5NEpTbmI1SUltRVFkdmZ0NUc2YzloV3l6aDZWUFVpQlIyNTJ4REZnb1dvSzBocWdGamIzMElJeDJFcUMtM1RKdmJUM1p3TGN0cndBbmJnSm1lbVppT014T0JaZHNxejFkZ18taUVVdDZFekhpV0RHN0Q1SmJjNk80V1dXTU1Ccmh6akZia3BQRW1paU1NNE5peldUVkI3NlJBeEw4di

• Enfin un traitement prometteur contre l'arthrose des doigts - Nice-Matin

  📰 Nice-Matin · 02/12/2019

  <a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPNWVQSVE3Tjg5VmJIOXprX0NzQTJJc28wcDV0Mm9BdDBZRVR6UVRIdlFqdG5qY2J2ZVd1NWI4aXhIX25BTmJNWDRReks1ZXVtTlBHLWhqanpQOUpyT3FFblloQkduMVNKWV9HYndzWEpQai1UUXllekU1cHNDLVRhTGNPZVp0eXdBVjR2UDFUTVVVWk5CQlRIa2tjd3BQQ0k?oc=5" target="_blank">Enfin un tra

• Inondations Nice - ina.fr

  📰 ina.fr · 06/11/1994

  <a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE53Z3RwYkRjOGRFVWFIejdrbzBLVHg1MWpqRWxSby1fZ2c3cVJPczZtQ3dlQ3kxR3JndWtiV2RKLUc4bnB0OHhTTkpaZmdPM0FCNU9STnphRWUzelJfVmppM2dmX3pSNnRiZ3RQRDBCcnZOM1Z2dkozMkRR?oc=5" target="_blank">Inondations Nice</a>&nbsp;&nbsp;<font color="#6f6f6f">ina.fr</f

Top publications · les plus citées

• 1

  Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

  BMJ (Clinical research ed.) · 2023

  📚 155 citations🎯 RCR 25.67Top 1% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract Objective To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors. Design Systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. Data sources Medline, Embase, and Cochrane Library to identify randomised controlled trials published between 1 January 1996 and 24 November 2021 that examined the effect of bisphosphonates, denosumab, selective oestrogen receptor modulators, parathyroid hormone receptor agonists, and romosozumab compared with placebo or active comparator. Eligibility criteria for selecting studies Randomised controlled trials that included non-Asian postmenopausal women with no restriction on age, when interventions looked at bone quality in a broad perspective. The primary outcome was clinical fractures. Secondary outcomes were vertebral, non-vertebral, hip, and major osteoporotic fractures, all cause mortality, adverse events, and serious cardiovascular adverse events. Results The results were based on 69 trials (&gt;80 000 patients). For clinical fractures, synthesis of the results showed a protective effect of bisphosphonates, parathyroid hormone receptor agonists, and romosozumab compared with placebo. Compared with parathyroid hormone receptor agonists, bisphosphonates were less effective in reducing clinical fractures (odds ratio 1.49, 95% confidence interval 1.12 to 2.00). Compared with parathyroid hormone receptor agonists and romosozumab, denosumab was less effective in reducing clinical fractures (odds ratio 1.85, 1.18 to 2.92 for denosumab v parathyroid hormone receptor agonists and 1.56, 1.02 to 2.39 for denosumab v romosozumab). An effect of all treatments on vertebral fractures compared with placebo was found. In the active treatment comparisons, denosumab, parathyroid hormone receptor agonists, and romosozumab were more effective than oral bisphosphonates in preventing vertebral fractures. The effect of all treatments was unaffected by baseline risk indicators, except for antiresorptive treatments that showed a greater reduction of clinical fractures compared with placebo with increasing mean age (number of studies=17; β=0.98, 95% confidence interval 0.96 to 0.99). No harm outcomes were seen. The certainty in the effect estimates was moderate to low for all individual outcomes, mainly because of limitations in reporting, nominally indicating a serious risk of bias and imprecision. Conclusions The evidence indicated a benefit of a range of treatments for osteoporosis in postmenopausal women for clinical and vertebral fractures. Bone anabolic treatments were more effective than bisphosphonates in the prevention of clinical and vertebral fractures, irrespective of baseline risk indicators. Hence this analysis provided no clinical evidence for restricting the use of anabolic treatment to patients with a very high risk of fractures. Systematic review registration PROSPERO CRD42019128391.

• 2

  Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024

  📚 61 citations🎯 RCR 20.33Top 1% NIH🔓 Open Access📄 PDF gratuit ↗
• 3

  Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial

  Nature medicine · 2023

  📚 42 citations🎯 RCR 5.47Top 7% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  AbstractFibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (n = 20) or placebo (n = 24) in period 1 (28 weeks), followed by an open-label period 2 (28 weeks; n = 43). The primary end points were safety and for period 1, the activity and size of HO lesions. All patients experienced at least one treatment-emergent adverse event during period 1, notably epistaxis, madarosis and skin abscesses. Five deaths (5 of 44; 11.4%) occurred in the open-label period and, while considered unlikely to be related, causality cannot be ruled out. The primary efficacy end point in period 1 (total lesion activity by PET–CT) was not met (P = 0.0741). As the development of new HO lesions was suppressed in period 1, the primary efficacy end point in period 2 was prospectively changed to the number of new HO lesions versus period 1. No placebo patients crossing over to garetosmab developed new HO lesions (0% in period 2 versus 40.9% in period 1; P = 0.0027). Further investigation of garetosmab in FOP is ongoing. ClinicalTrials.gov identifier NCT03188666.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

  Audiovisual2020Adis Journals

  <strong>Article full text</strong> <br> The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online

• Concentric or eccentric physical activity for patients with symptomatic osteoarthritis of the knee: a randomized prospective study

  Collection2022SAGE Journals

  Background:Knee osteoarthritis–related pain limits physical function and leads to functional disability. Physical activity is one of the central recommendations for the management of knee osteoarthritis. Although concent

• Deletion of PPARα in mouse brown adipocytes increases their De Novo Lipogenesis

  Other2025Elsevier

  Objective: Peroxisome Proliferator-Activated Receptors (PPARs) are nuclear receptors involved in the control of lipid metabolism. The PPARα isoform is highly expressed in brown adipose tissue (BAT). However, its precise

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche